• Pharma

    Digitally-enabled pharmacotherapy, theragnostics, and mental health endpoints.

    The greatest challenges facing the pharmaceutical industry today include changing patient expectations, increased self-medication, difficulties in identifying novel medicines for incurable diseases, high payer scrutiny of pharma-economic performance, the trend for governments to favour prevention over treatment, and access to emerging markets. Partnering with Mobio helps turn these challenges into opportunities.

    Patient Testimonials

     

    "…it was helping me get through my post cancer treatments and my cancer that has been a very very rough journey."

    Breast cancer survivor (double mastectomy)

     

     

    "... this [digital therapeutic] forced me to block out the world and say okay, this moment is mine right now, and I'm going to enjoy this moment for myself."

    Testicular cancer survivor (chemotherapy)

     

    "…I felt like it was an actual meditation – like they were actually there with me."

    Kidney cancer survivor (immunotherapy)

     

     

  • What we offer

    ✓ Decentralised clinical trial infastructure, inclusive of remote e-consent and participant tirage

    ✓ Objective, unbiased data on mental health and cognitive acuity

    ✓ Combination treatment, enhancing pharmaceutical adherance by reducing side-effects and visualising impact

    Rx + DTx Pairing

    Improve patient experience and reduce side-effects, creating greater adherance.

    Standalone DTx

    Generate compound-agnostic revenue

    Clinical Endpoints

    Capture objective biometrics remotely.

  • Certifications

    Mobio Interactive’s digital therapeutic platform “Dawn DTx” has CE MDR Class 1, DCB 0129 ,and ISO 27001-2022 certification; and is GDPR-, HIPAA- and PHIPA-compliant.

    Validating the accuracy of our digital biomarkers and the efficacy of our digital theragnostic platform, Dawn DTx, Mobio has published over 20 peer-reviewed papers to date from over a dozen completed clinical studies.

    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More